Tharimmune Inc. Market Cap ($130.84 Million)
Market Cap & Net Worth: Tharimmune Inc. (THAR)
Tharimmune Inc. market cap. Tharimmune Inc. (NASDAQ:THAR) has a market capitalization of $130.84 Million ($130.84 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #17969 globally and #4232 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tharimmune Inc.'s stock price $3.31 by its total outstanding shares 39529847 (39.53 Million). Also see Tharimmune Inc. (THAR) cash flow conversion for how efficiently the company converts equity into cash flow.
Tharimmune Inc. Market Cap History (2022–2026)
Tharimmune Inc. market cap history from 2022 to 2026. Data shows change from $5.78 Billion to $130.84 Million (-75.30% CAGR). Check Tharimmune Inc. (THAR) share price today for real-time trading data and today's change.
Index Memberships
Tharimmune Inc. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.01% | #490 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #1738 of 3165 |
Weight: Tharimmune Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Tharimmune Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tharimmune Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Tharimmune Inc. (THAR) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of THAR by Market Capitalization
Companies near Tharimmune Inc. in the global market cap rankings as of November 4, 2026. Also see THAR total assets for a full breakdown of the balance sheet.
Key companies related to Tharimmune Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Tharimmune Inc. (2022–2026)
Market capitalization of Tharimmune Inc. from 2022 to today. Between 2022 and today, Tharimmune Inc.'s market cap moved from $5.78 Billion to $ 130.84 Million, with a yearly change of -75.30%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $130.84 Million | +9.24% |
| 2025 | $119.78 Million | +49.26% |
| 2024 | $80.25 Million | -73.41% |
| 2023 | $301.81 Million | -94.78% |
| 2022 | $5.78 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Tharimmune Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $130.84 Million USD |
| MoneyControl | $130.84 Million USD |
| MarketWatch | $130.84 Million USD |
| marketcap.company | $130.84 Million USD |
| Reuters | $130.84 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Tharimmune Inc.
Tharimmune, Inc. focuses on leveraging Canton Coin and supporting the Canton network to advance institutional blockchain adoption and the digitization of financial markets. It is also involved in the clinical-stage biotech research and development activities. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. w… Read more